Seven months longer, twice the response: a new option lifts survival in advanced womb cancer

For women whose womb (endometrial) cancer has come back or spread, chemotherapy has long been the fallback — and its limits are well known. In a randomised Phase 3 trial presented at the European Society for Medical Oncology Congress and published in The Lancet, the drug sacituzumab tirumotecan helped patients live about seven months longer than chemotherapy and doubled the share whose tumours shrank, cutting the risk of death by 32%. The TroFuse-005 trial, led by oncologist Domenica Lorusso, compared the targeted drug directly against standard chemotherapy in advanced or recurrent disease. Longer life, from a treatment aimed at the cancer rather than the whole body, is the kind of progress patients in this group have waited years to see.

SDG 3 · Good health and well-being — Mechanism: tech innovation